Cas 1050512-29-2,methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate

1050512-29-2

Post Buying Request

Basic information

Product Name: methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate
Synonyms: methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate
CAS NO:1050512-29-2
Molecular Formula:
Molecular Weight: 468.493
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate(CAS DataBase Reference)
NIST Chemistry Reference: methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate(1050512-29-2)
EPA Substance Registry System: methyl 4-methoxy-2-[(3-{[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino}quinoxalin-2-yl)amino]benzoate(1050512-29-2)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1050512-29-2(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1050512-29-2 Suppliers

Recommended suppliers

1050512-29-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1050512-29-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,0,5,1 and 2 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1050512-29:
(9*1)+(8*0)+(7*5)+(6*0)+(5*5)+(4*1)+(3*2)+(2*2)+(1*9)=92
92 % 10 = 2
So 1050512-29-2 is a valid CAS Registry Number.

1050512-29-2Upstream product

1050512-29-2Downstream Products

1050512-29-2Relevant academic research and scientific papers

QUINOXALINE COMPOUNDS AND USE THEREOF

-

Page/Page column 113-114, (2008/12/08)

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1050512-29-2